Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics - 2009-2023

BioNewsCast Press Release Distribution Service

Statins: The World Market, 2009-2024

Liver Cancer Drug Pipeline Update 2008

Bioinformatics Markets

New Products

Live Cell & Kinetic HCS Imaging Trends 2008

2008 Trends to Watch: Healthcare Technology

2009 Trends to Watch: Healthcare Technology

Biosimilars Series: Stakeholder Analysis

Biotech M&A Strategies: Deal assessments, trends and future prospects

Building a Network of Networks to Achieve Interoperability in Healthcare (Strategic Focus)

Business Trends - Healthcare Technology (Customer Focus)

Claims Processing for Healthcare Payers (Market Model)

Clinical Decision Support in Healthcare - One step closer to the Omniscient Clinician (Strategic Focus)

Commercial and Pipeline Insight: ADHD - Immature adult market continues to offer greatest commercial potential

BioPortfolio | Biotechnology Information Institute

Biopharmaceutical Expression Systems and Genetic Engineering Technologies
New expression systems and recent improvements available for current systems have the potential to revolutionize the biopharmaceutical industry!Lower costs and efficiencies of newer expression systems are driving these changes.

This book provides you with the information you need to make the shift to increased productivity. As reflected by currently marketed products, since the advent of genetic engineering in the 1970s, there has been little basic change in the technologies used for commercial-scale manufacture of biopharmaceutical products.

Nearly all current products are manufactured using much the same old, familiar technologies – primarily using Esherichia coli (E. coli bacterium), Chinese hamster ovary (CHO) cells and the yeast Saccharomyces cerevisiae (S. cerevisiae) as hosts – technologies invented in the 1970s and commercialized in the 1980s.

Advances in Biopharmaceutical Technology in India
BioPlan Associates in India can provide you the most up-to-date news and perspective on events and trends in this rapidly-changing biopharmaceutical industry. Whether you require basic information, or extensive support in partnering with the right companies in India, BioPlan will work with you to meet your needs.

Directory of Top 60 Biopharmaceutical Manufacturers in China
The first edition of the BioPlan China Biopharmaceutical Index includes the Top 60 Biopharmaceutical Companies in China, with detailed profiles of their business focus, products, revenues, R&D and business strategies, international objectives, partnering strategies, and marketing activities. In addition, subscribers will receive on-going updates to activities and trends in China as the country’s biopharmaceutical industry expands. Our China Biopharmaceutical Index and our Top 60 Directory provide you information on trending of activities and changes occurring in the region. Be sure to keep up-to-date on Who’s Who in China. This report will help ensure you’re current, and have a solid understanding of this dynamic, rapidly changing market.

Directory of Top 60 Biopharmaceutical Manufacturers in India
The first edition of the BioPlan India Biopharmaceutical Index, includes the Top 60 Biopharmaceutical Companies in India, with detailed profiles of their business focus, products, revenues, R&D and business strategies, international objectives, partnering strategies, and marketing activities. In addition, subscribers will receive on-going updates to activities and trends in India as the country's biopharmaceutical industry expands.

Biopharma Products US & Europe, 6th Ed
This exceptional 2-volume, comprehensive biopharmaceutical reference is now in its 6th Edition! It is the ORIGINAL, and only biopharmaceutical reference--invaluable general, technical, marketing, manufacturing, and competitive information. Over 500 comprehensive, individual monographs in 1,602 packed pages, covering all US, and European biotechnology products on the market. Includes many biodefense and biogeneric products. Detailed descriptions and indexing, legal, manufacturing, competitive, marketing, technological and regulatory intelligence; includes unique and hard- to-find primary information. And now available in PDF and Web-database versions!

Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd Edition
A Comprehensive Study of the Science, Technology and Business of Biopharmaceutical Manufacturing.

Published by the ASM Press [American Society for Microbiology] and BioPlan Associates, Inc., November 2007.

Includes: 1,224 pages, 34 Chapters, 94 Authors, 290 Figures & Tables, 1345 References and 18 Reviewers

PART 1

Emerging Technologies, Scientific Advancements

PART 2

Business, Capacity and Regulatory Issues

5th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, March 2008
This comprehensive look at the state of worldwide biopharmaceutical manufacturing provides the only on-going assessment of manufacturing capacity and production in this $80 billion global industry. You will find current, quantitative information from 434 worldwide biopharmaceutical developers and contract manufacturers, and over 120 suppliers to the industry. Covers year 2007.

Coverage includes:

In-depth analysis and summary of the key survey findings, trends and implications for industry-wide biomanufacturing capacity and biotherapeutic production

Comparison of production by biotherapeutic developers and contract manufacturing organizations

Current and future potential industry bottlenecks

Trend analysis in this 5th in a series of annual biopharmaceutical manufacturing industry evaluations

Projected capacity bottlenecks, and how they might be resolved

This edition includes the joint industry expertise from BioPlan Associates, and many industry consultants and experts

Advances in Biopharmaceutical Technology in China
A Society for Industrial Microbiology and BioPlan Associates co-publication

Every organization has a China strategy, though for many of us it is simply “ignore it.” A great opportunity exists in working with China and implementing an effective company strategy. However, winning in Asia in the new millennium will require fundamental changes in partnerships between western and Asian companies. Every company faces the question “What should our China strategy be?” But to neglect China is to forego opportunities to gain efficiency in most of the things we are trying to do. China provides opportunities that allow us to do different things and not just do things differently.

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions